Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

Leukemia

Volumn 16, Issue 6, 2002, Pages 1182-1188

  Cheung, W C ^a   Van Ness, B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

IL 6 signal transduction; Multiple myeloma; STAT3

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 130; GROWTH FACTOR; INTERLEUKIN 6; MYC PROTEIN; PROTEIN BCL XL; STAT3 PROTEIN;

ANTIBODY PRODUCING CELL; ARTICLE; B LYMPHOCYTE; CELL DEATH; CELL FATE; CELL KINETICS; CELL MATURATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE DIFFERENTIATION; MITOSIS INHIBITION; MOLECULAR BIOLOGY; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 85014285855     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402481     Document Type: Article

References (37)

1. Roles of STAT3 in mediating the cell growth, differetiation and survival signals relayed through the IL-6 family of cytokine receptors
2. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway
3. Interleukin-6: An overview
4. Cytokines involved in B-cell differentiation and their sites of action
5. Regulation of terminal differentiation of human B-cells by IL-6
6. The bone marrow: The major source of serum immunoglobulins, but still a neglected site of antibody formation
7. Growth control mechanisms in multiple myeloma
8. Heterogeneity in therapeutic response of genetically altered myeloma cell lines to IL-6, dexamethasone, doxorubicin, and melphalan
9. The bone marrow stromal microenvironment influences myeloma therapeutic responses in vitro
10. Interleukin-6 prevents dexamethasone-induced myeloma cell death
11. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone
12. Signaling mechanisms through gp130: A model of the cytokine system
13. STATs in oncogenesis
14. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
15. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine and hybridomas
16. Studying signal transduction in neuronal cells: The Trk/NGF system
17. The Jak-Stat pathway in normal and perturbed hematopoiesis
18. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp130 important for ligand-induced endocytosis of the IL-6 receptor
19. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis
20. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
21. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL
22. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells
23. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line
24. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells
25. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to grb2 via tyrosine 584
26. Shp-2 tyrosine phosphatase: Signaling one cell or many
27. Dissection of signaling cascades through gp130 in vivo: Reciprocal roles for STAT3- and SHP2-mediated signals in immune response
28. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis
29. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition
30. Control of myeloid differentiation and survival by Stats
31. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway
32. STAT3-mediated astrocyte differentiation from mouse fetal neuroepithelial cells by mouse oncostatin M
33. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells
34. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6
35. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors
36. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells
37. Inhibitors keep cytokines in check